Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 13/20 | 0.52 |
| ▸ | GUCY1A2 | P33402 | 13/20 | 0.52 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.52 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20309887 | 0.92 | GUCY1B2 (0.54) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ALDH1A1 | |
| SCHEMBL20284705 | 0.87 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ALDH1A1 | |
| SCHEMBL20309891 | 0.87 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL20310014 | 0.87 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ALDH1A1 | |
| SCHEMBL16806829 | 0.86 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ALDH1A1 | |
| SCHEMBL20309905 | 0.85 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL17621215 | 0.85 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ALDH1A1 | |
| SCHEMBL23434823 | 0.83 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL20309975 | 0.82 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16082339 | 0.81 | GUCY1B2 (0.77) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210161893-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | GLS2, GPR119, PRKG1 | GUCY1B2 16/4885GUCY1A2 9/4885GUCY1A1 8/4885 |
| US-20210161893-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | GLS2, GPR119, PRKG1 | GUCY1B2 16/4885GUCY1A2 9/4885GUCY1A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.